Paolini, John F.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 9,430

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 608

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Hankey, G. J., Patel, M. R., Stevens, S. R., Becker, R. C., Breithardt, G., Carolei, A., Diener, H.-C., Donnan, G. A., Halperin, J. L., Mahaffey, K. W., et al. (2012) · The Lancet Neurology

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 354

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 251

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

De Luca, G., Cavalli, G., Campochiaro, C., Della-Torre, E., Angelillo, P., Tomelleri, A., Boffini, N., Tentori, S., Mette, F., Farina, N., et al. (2020) · The Lancet Rheumatology

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 202

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Sofen, H., Bissonnette, R., Yosipovitch, G., Silverberg, J. I., Tyring, S., Loo, W. J., Zook, M., Lee, M., Zou, L., Jiang, G.-L., et al. (2023) · eClinicalMedicine

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 108

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 97

560 KPL-716, anti-Oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis

Mikhak, Z., Bissonnette, R., Siri, D., Tyring, S. K., Tessari, E., Gandhi, R., Fang, F., & Paolini, J. F. (2019) · Journal of Investigative Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 21